Novo Nordisk A/S (NYSE:NVO) Stock Position Reduced by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC reduced its stake in Novo Nordisk A/S by 3.6%, owning 2.9 million shares valued at $202.4 million as of the latest SEC filing.
• Novo Nordisk's share price has dropped 21.8%, currently trading at $53.97, significantly below its 52-week high of $139.74.
• The company reported a quarterly earnings per share (EPS) of $0.92, meeting analysts' expectations, and had a net margin of 34.52% during the quarter.

Natixis Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,914,104 shares of the company's stock after selling 109,909 shares during the quarter. Natixis Advisors LLC owned approximately 0.06% of Novo Nordisk A/S worth $202,355,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in shares of Novo Nordisk A/S by 113.1% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 43,776 shares of the company's stock valued at $3,766,000 after purchasing an additional 23,238 shares during the period. Physician Wealth Advisors Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth $69,000. Wellington Management Group LLP grew its holdings in Novo Nordisk A/S by 135.3% during the fourth quarter. Wellington Management Group LLP now owns 830,435 shares of the company's stock worth $71,434,000 after acquiring an additional 477,557 shares during the period. Finally, Hoey Investments Inc. grew its holdings in Novo Nordisk A/S by 735.3% during the fourth quarter. Hoey Investments Inc. now owns 568 shares of the company's stock worth $49,000 after acquiring an additional 500 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 6.0%

NYSE:NVO traded down $3.01 on Thursday, hitting $47.02. 50,205,463 shares of the stock were exchanged, compared to its average volume of 15,299,037. The stock has a market cap of $209.94 billion, a PE ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average of $69.64 and a 200-day moving average of $72.95. Novo Nordisk A/S has a fifty-two week low of $46.90 and a fifty-two week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVO. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday. Two analysts have rated the stock with a sell rating, seven have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $93.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.